Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2014 Sep;31(9):1086-92.
doi: 10.1111/dme.12512. Epub 2014 Jun 19.
Affiliations
- PMID: 24890138
- DOI: 10.1111/dme.12512
Randomized Controlled Trial
Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial
Z Punthakee et al. Diabet Med. 2014 Sep.
Abstract
Aims: Thiazolidinediones reduce ectopic fat, increase adiponectin and reduce inflammatory adipokines, fatty acids and glucose in people with Type 2 diabetes. We aimed to measure these effects in people with impaired fasting glucose and/or impaired glucose tolerance.
Methods: After approximately 3.5 years of exposure to rosiglitazone 8 mg (n = 88) or placebo (n = 102), 190 DREAM trial participants underwent abdominal computed tomography and dual-energy X-ray absorptiometry scans. Visceral and subcutaneous adipose tissue areas, estimated hepatic fat content, total fat and lean mass were calculated and changes in levels of fasting adipokines, free fatty acids, glucose and post-load glucose were assessed.
Results: Compared with the placebo, participants on rosiglitazone had no difference in lean mass, had 4.1 kg more body fat (P < 0.0001) and 31 cm(2) more subcutaneous abdominal adipose tissue area (P = 0.007). Only after adjusting for total fat, participants on rosiglitazone had 23 cm² less visceral adipose tissue area (P = 0.01) and an 0.08-unit higher liver:spleen attenuation ratio (i.e. less hepatic fat; P = 0.02) than those on the placebo. Adiponectin increased by 15.0 μg/ml with rosiglitazone and by 0.4 μg/ml with placebo (P < 0.0001). Rosiglitazone's effect on fat distribution was not independent of changes in adiponectin. Rosiglitazone's effects on fasting (-0.36 mmol/l; P = 0.0004) and 2-h post-load glucose (-1.21 mmol/l; P = 0.0008) were not affected by adjustment for fat distribution or changes in adiponectin or free fatty acids.
Conclusions: In people with impaired fasting glucose/impaired glucose tolerance, rosiglitazone is associated with relatively less hepatic and visceral fat, increased subcutaneous fat and increased adiponectin levels. These effects do not appear to explain the glucose-lowering effect of rosiglitazone.
© 2014 The Authors. Diabetic Medicine © 2014 Diabetes UK.
Similar articles
- Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P. Iozzo P, et al. Diabetes Care. 2003 Jul;26(7):2069-74. doi: 10.2337/diacare.26.7.2069. Diabetes Care. 2003. PMID: 12832315 - Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Kim HJ, Jung TW, Kang ES, Kim DJ, Ahn CW, Lee KW, Lee HC, Cha BS. Kim HJ, et al. Metabolism. 2007 May;56(5):676-85. doi: 10.1016/j.metabol.2006.12.017. Metabolism. 2007. PMID: 17445544 - Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.
Samaras K, Wand H, Law M, Emery S, Cooper DA, Carr A. Samaras K, et al. Curr HIV Res. 2009 Jul;7(4):454-61. doi: 10.2174/157016209788680589. Curr HIV Res. 2009. PMID: 19601783 - Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue.
Lafontan M, Girard J. Lafontan M, et al. Diabetes Metab. 2008 Sep;34(4 Pt 1):317-27. doi: 10.1016/j.diabet.2008.04.001. Epub 2008 Jun 11. Diabetes Metab. 2008. PMID: 18550411 Review. - The role of fat topology in the risk of disease.
Matsuzawa Y. Matsuzawa Y. Int J Obes (Lond). 2008 Dec;32 Suppl 7:S83-92. doi: 10.1038/ijo.2008.243. Int J Obes (Lond). 2008. PMID: 19136997 Review.
Cited by
- Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions.
Okada S, Konishi M, Ishii H. Okada S, et al. BMJ Case Rep. 2016 Feb 25;2016:bcr2015213637. doi: 10.1136/bcr-2015-213637. BMJ Case Rep. 2016. PMID: 26917795 Free PMC article. - Youth-onset type 2 diabetes mellitus: an urgent challenge.
Bjornstad P, Chao LC, Cree-Green M, Dart AB, King M, Looker HC, Magliano DJ, Nadeau KJ, Pinhas-Hamiel O, Shah AS, van Raalte DH, Pavkov ME, Nelson RG. Bjornstad P, et al. Nat Rev Nephrol. 2023 Mar;19(3):168-184. doi: 10.1038/s41581-022-00645-1. Epub 2022 Oct 31. Nat Rev Nephrol. 2023. PMID: 36316388 Free PMC article. Review. - A review on associated factors and management measures for sarcopenia in type 2 diabetes mellitus.
Zhang Y, Zhang K, Huang S, Li W, He P. Zhang Y, et al. Medicine (Baltimore). 2024 Apr 19;103(16):e37666. doi: 10.1097/MD.0000000000037666. Medicine (Baltimore). 2024. PMID: 38640276 Free PMC article. Review. - Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016.
Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Andes LJ, et al. JAMA Pediatr. 2020 Feb 1;174(2):e194498. doi: 10.1001/jamapediatrics.2019.4498. Epub 2020 Feb 3. JAMA Pediatr. 2020. PMID: 31790544 Free PMC article. - Adipocyte Heterogeneity Underlying Adipose Tissue Functions.
Yang Loureiro Z, Solivan-Rivera J, Corvera S. Yang Loureiro Z, et al. Endocrinology. 2022 Jan 1;163(1):bqab138. doi: 10.1210/endocr/bqab138. Endocrinology. 2022. PMID: 34223880 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical